Ultomiris® (ravulizumab-cwvz) – Expanded indication
June 7, 2021 - Alexion announced the FDA approval of Ultomiris (ravulizumab-cwvz), for the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
Download PDF
